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1. INTRODUCTION {#mgg31226-sec-0005}
===============

Pancreatic cancer is one of the hardest to treat malignancies. According to GLOBOCAN 2018 estimates, pancreatic cancer is the 11th most common type of cancer worldwide, with 458,918 new cases (accounting for 2.5% of all cases of cancer) and 432,242 deaths (4.5% of all deaths caused by cancer) (Bray et al., [2018](#mgg31226-bib-0004){ref-type="ref"}). Additionally, the number of cancer death ranked the seventh in developed countries (Bray et al., [2018](#mgg31226-bib-0004){ref-type="ref"}), and its number of cancer death ranked third in the USA (Siegel, Miller, & Jemal, [2019](#mgg31226-bib-0040){ref-type="ref"}). In China, it was the 10th most common malignant carcinoma in 2015 (2.42% of all cancer cases), and it is the sixth leading cause of cancer‐associated death (3.64% of all cancer‐associated deaths) (Zheng et al., [2019](#mgg31226-bib-0053){ref-type="ref"}).

The etiology of pancreatic cancer has been extensively studied by numerous meta‐analyses and pooled analyses. Thus far, several risk factors can be divided into two primary categories: Modifiable and non‐modifiable. The former includes smoking, alcohol, dietary factors, obesity, and exposure to toxic substances, whereas the latter includes ethnicity, sex, age, family history of pancreatic cancer, diabetes mellitus, genetic factors, chronic infections, non‐O blood group, and chronic pancreatitis (Midha, Chawla, & Garg, [2016](#mgg31226-bib-0028){ref-type="ref"}). However, the specific etiology has been not defined. Although several pathological types of pancreatic malignancies have been identified, pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor are the most prevalent, which account for 90% and 5%, respectively (Hackeng, Hruban, Offerhaus, & Brosens, [2016](#mgg31226-bib-0017){ref-type="ref"}). Additionally, patients with an early stage of pancreatic cancer do not typically exhibit symptoms. However, as the cancer progresses, it may physically manifest as a gradual onset of nonspecific symptoms, such as jaundice, light‐colored stools, abdominal pain, weight loss, and fatigue (Siegel, Miller, & Jemal, [2018](#mgg31226-bib-0039){ref-type="ref"}). The available diagnostic tests for detection include measuring the blood levels of cancer antigen 19--9, abdominal ultrasonography, tri‐phasic pancreatic protocol CT, magnetic resonance imaging, and endoscopic ultrasound‐guided fine‐needle aspiration for cytological diagnosis (the sensitivity of which is reported to be \~80%) (Longnecker, Karagas, Tosteson, & Mott, [2000](#mgg31226-bib-0027){ref-type="ref"}). Nonetheless, they are nonspecific and may miss numerous patients with early stage pancreatic cancer (De La Cruz, Young, & Ruffin, [2014](#mgg31226-bib-0010){ref-type="ref"}). Therefore, pancreatic cancer is usually diagnosed at the advanced stage, and 80%--90% of patients present with unresectable tumors at the first diagnosis (Rawla, Sunkara, & Gaduputi, [2019](#mgg31226-bib-0030){ref-type="ref"}). Once a definite diagnosis has been made, surgery, chemotherapy, and radiotherapy are traditionally used to extend the patients' survival and/or relieve their symptoms. However, for patients with advanced‐stage pancreatic cancer, there is still no definitive or effective cure (Mohammed, Van Buren, & Fisher, [2014](#mgg31226-bib-0029){ref-type="ref"}).

Prevention, early detection, and curing the disease in the early stages are key to reduce the morbidity and mortality rates. Novel etiological agent or more specific diagnostic tools may result in improved outcomes for patients. Thus, there is a need for ongoing evaluation for the epidemiology of this malignancy. Among the factors which need to be assessed, genetic variations or mutations serve an important role in the increased risk of pancreatic cancer (Ghiorzo, [2014](#mgg31226-bib-0014){ref-type="ref"}). Of the patients with pancreatic cancer, \~10% possess a genetic predisposition to developing the malignancy (Shi, Daniels, & Hruban, [2008](#mgg31226-bib-0038){ref-type="ref"}). Several germline mutations have been demonstrated to be involved in hereditary forms of pancreatic cancer, such as *BRCA1* (OMIM \# 113,705)*, BRCA2* (OMIM \# 600,185)*, PALB2* (OMIM \# 610,355)*, ATM* (OMIM \# 607,585)*, APC* (OMIM \# 611,731)*, MLH1* (OMIM \#120436)*, MSH2* (OMIM \# 609,309)*, MSH6* (OMIM \# 600,678)*, PMS2* (OMIM \# 600,259)*, PRSS1* (OMIM \# 276,000), and *STK11* (OMIM \# 602,216) (Solomon, Das, Brand, & Whitcomb, [2012](#mgg31226-bib-0041){ref-type="ref"}; Vincent, Herman, Schulick, Hruban, & Goggins, [2011](#mgg31226-bib-0044){ref-type="ref"}).

The ATP‐binding cassette subfamily B member 1 (*ABCB1* \[OMIM \#171050\]), also known as multidrug resistance gene 1, encodes a transmembrane P‐glycoprotein (P‐gp). This protein functions to efflux of endogenous metabolites and toxic xenobiotics, including intracellular carcinogens, suggesting its protective role against carcinogenesis. P‐gp also serves an important role in the reduction of drug response, through modulating absorption, metabolism, and promoting elimination of drugs from cells. P‐gp also activates lymphocytes during the immune response (Hodges et al., [2011](#mgg31226-bib-0020){ref-type="ref"}). It is speculated that genetic polymorphisms of *ABCB1* may result in variations in the expression levels of the mRNA transcript and protein, or result in misfolded proteins, and reduced or altered substrate specificity, which will likely influence drug pharmacokinetics or disease outcome (Fung & Gottesman, [2009](#mgg31226-bib-0013){ref-type="ref"}). Several studies have reported the association between *ABCB1* polymorphisms with cancer risk, and the results were not consistent absolutely (He, Mo, Zhang, & Liu, [2013](#mgg31226-bib-0019){ref-type="ref"}; Ruiz‐Pinto et al., [2016](#mgg31226-bib-0032){ref-type="ref"}; Sabahi et al., [2010](#mgg31226-bib-0033){ref-type="ref"}; Sam et al., [2007](#mgg31226-bib-0034){ref-type="ref"}; Yan et al., [2019](#mgg31226-bib-0046){ref-type="ref"}).

Obesity is associated with an increased risk of pancreatic cancer (Davoodi, Malek‐Shahabi, Malekshahi‐Moghadam, Shahbazi, & Esmaeili, [2013](#mgg31226-bib-0009){ref-type="ref"}) and it may increase the incidence and mortality of pancreatic cancer (Berrington de Gonzalez, Sweetland, & Spencer, [2003](#mgg31226-bib-0003){ref-type="ref"}; Calle, Rodriguez, Walker‐Thurmond, & Thun, [2003](#mgg31226-bib-0005){ref-type="ref"}). Abnormal lipid metabolism promotes pancreatic tumorigenesis (Guillaumond et al., [2015](#mgg31226-bib-0015){ref-type="ref"}; Ying et al., [2016](#mgg31226-bib-0048){ref-type="ref"}). The apolipoprotein B (APOB) protein forms an integral part of chylomicrons and very low‐density lipoproteins during lipoprotein metabolism. Several SNPs in *APOB* (OMIM \# 107,730) have been reported, although their significance to cancer has not been studied, to the best of our knowledge. Therefore, whether they influence the progression of pancreatic carcinoma remains to be determined.

Caveolin 1 (CAV1) serves an important role in cell signaling regulation and acts as a scaffold involved in various signaling ways. For example, the caveolin‐scaffolding domain negatively regulates the activity of numerous signaling molecules, including endothelial nitric oxide synthase (Ju, Zou, Venema, & Venema, [1997](#mgg31226-bib-0022){ref-type="ref"}) and epidermal growth factor receptor (Couet, Sargiacomo, & Lisanti, [1997](#mgg31226-bib-0008){ref-type="ref"}). *CAV1* (OMIM \# 601,047) is expressed in a variety of tumor cells and exhibits carcinogenic and tumor suppressive functions dependent on the specific type of cancer and stage (Gupta, Toufaily, & Annabi, [2014](#mgg31226-bib-0016){ref-type="ref"}). Taken together, previous studies suggested that *CAV1* expression may inhibit tumor growth in the early stages of cancer, and promote its invasion and metastasis in the later stages (Shatz & Liscovitch, [2008](#mgg31226-bib-0037){ref-type="ref"}). To date, numerous studies have explored the association between genetic polymorphisms of *CAV1* and hepatocellular, colorectal, and gastric cancers (Hsu et al., [2013](#mgg31226-bib-0021){ref-type="ref"}; Yang et al., [2010](#mgg31226-bib-0047){ref-type="ref"}; Zhang, Hu, et al., [2014](#mgg31226-bib-0052){ref-type="ref"}).

Nicotinamide phosphoribosyltransferase (NAMPT) was initially identified as a pre‐B‐cell colony‐enhancing factor. NAMPT is also a rate‐limiting enzyme in NAD biosynthesis, which is crucial for numerous vital cellular processes, genomic stability, and organismal metabolic homeostasis (Shackelford, Mayhall, Maxwell, Kandil, & Coppola, [2013](#mgg31226-bib-0036){ref-type="ref"}; Ying, [2008](#mgg31226-bib-0049){ref-type="ref"}). Additionally, NAMPT is involved in angiogenesis by activating the extracellular signal‐regulated kinase 1/2 pathway, and increasing the expression of vascular endothelial growth factor and matrix metalloproteinase 2/9 (Kim et al., [2007](#mgg31226-bib-0024){ref-type="ref"}). *NAMPT* (OMIM \# 608,764) is highly evolutionarily conserved, suggesting that even small genetic variations may profoundly affect its protein expression, function, and subsequent dependent events.

Based on the above, certain SNPs of these proteins, which may affect protein expression, structure, or function, may be associated with genetic susceptibility to PDAC. However, to the best of our knowledge, there are no studies which have investigated the potential association between these SNPs and the risk of PDAC. Thus, the aim of the present study was to analyze the relationships between SNPs of *ABCB1* (rs1045642 \[HGVS Name: g.208920T\>C\], rs3789243 \[HGVS Name: g.126679T\>C\], rs4148737 \[HGVS Name: g.176413A\>G\]), *APOB* (rs693 \[HGVS Name: g.39751C\>T\], rs1042031 \[HGVS Name: g.46193G\>A\]), *CAV‐1* (rs12672038 \[HGVS Name: g.27268G\>A\], rs1997623 \[HGVS Name: g.5522A\>C\], rs3807987 \[HGVS Name: g.19996G\>A\], rs7804372 \[HGVS Name: g.34390T\>A\]), and *NAMPT* (rs9034 \[HGVS Name: c.\*1473T\>C\], rs2505568 \[HGVS Name: g.1929A\>T\], rs61330082 \[HGVS Name: g.106286419G\>A\]), and the hereditary susceptibility of PDAC in Chinese patients.

2. MATERIALS AND METHODS {#mgg31226-sec-0006}
========================

2.1. Study participants {#mgg31226-sec-0007}
-----------------------

Between January 2015 and December 2018, 273 patients with PDAC (165 males and 108 females) who visited Shandong Provincial Qianfoshan Hospital were recruited. All diagnoses were confirmed by qualified pathological analysis of surgical specimens or endoscopic ultrasound‐guided fine‐needle aspiration. Every slide was confirmed by two pathologists in Shandong Provincial Qianfoshan Hospital independently, while the disagreement was resolved by the senior pathologists. None of the patients recruited received chemotherapy or any other treatments for PDAC prior to recruitment. Moreover, patients with incomplete clinical information and histories of previous cancers or autoimmune diseases were excluded in this study.

The control group composed of 269 healthy and genetically unrelated individuals (130 males and 139 females), with age between 25 and 80 years, randomly selected from Shandong permanent residents over the same period. They were voluntary participants without any known history of caner, psychological disorders, autoimmune diseases of the pancreas, cardiocerebral vascular diseases, or infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

Each participant provided written informed consent for participation in the study, and their demographic and lifestyle characteristics were collected and recorded by one‐on‐one interviews. A history of regular cigarette smoking was defined as ≥1 cigarette per day for ≥12 months, or ≥18 packs for 1 year, while individuals drinking Chinese liquor ≥50 ml, or beer ≥200 ml biweekly for 12 months were thought as positive history of drinking.

2.2. DNA extraction {#mgg31226-sec-0008}
-------------------

A total of 3 ml of peripheral blood was drawn from each patient, and the genomic DNA was extracted using a Blood DNA kit according to the manufacturer\'s protocol (Omega Bio‐Tek, Inc.).

2.3. Genotyping {#mgg31226-sec-0009}
---------------

Genomic DNA was amplified using PCR. The sequencing primers used were the same as previous studies (Al‐Bustan, Alnaqeeb, Annice, Ebrahim, & Refai, [2014](#mgg31226-bib-0001){ref-type="ref"}; Caronia et al., [2011](#mgg31226-bib-0006){ref-type="ref"}; He et al., [2013](#mgg31226-bib-0019){ref-type="ref"}; Wang, Zhang, Liu, Xu, & Chen, [2014](#mgg31226-bib-0045){ref-type="ref"}; Zhang et al., [2015](#mgg31226-bib-0050){ref-type="ref"}). PCR amplification was performed in a total of 25‐µl reaction mixture, containing 100--150 ng genomic DNA, 0.5 μl of each primer (10 μM each; Shanghai Boshang Biotechnology Co., Ltd.), 0.5‐μl dNTP (10 mM), and 1.5 U Taq DNA polymerase (Takara Bio, Inc.). The thermocycling conditions were: Initial denaturation for 2 min at 94°C; followed by 38 cycles of 30 s at 94.0°C, 50 s at the respective annealing temperatures and 1 min at 72.0°C; and a final extension step of 5 min at 72.0°C. All PCR products were run on 2% agarose gels and imaged. Genotypes were identified using direct Sanger sequencing (Shanghai Boshang Biotechnology Co., Ltd.).

2.4. Statistical analysis {#mgg31226-sec-0010}
-------------------------

Comparison of age distribution between the two groups was performed using a Mann--Whitney U test. Differences in the other demographic variables were compared using a McNemar test. To verify that all subjects were selected from a representative population, a χ^2^ goodness‐of‐fit test was used to test genotypes for Hardy--Weinberg equilibrium. PHASE software (version 2.1, University of Chicago) haplotype and haplotype frequencies were constructed and estimated. The odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using unconditional logistic regression models. The adjusted ORs and 95% CIs were derived from logistic models adjusted for age, sex, smoking, alcohol consumption, diabetes, and family history of cancer. All statistical analyses were two‐sided and performed in Stata 15.1 (StataCorp LP). *p* \< .05 was considered to indicate a statistically significant difference.

3. RESULTS {#mgg31226-sec-0011}
==========

3.1. Distribution of patient characteristics {#mgg31226-sec-0012}
--------------------------------------------

Table [1](#mgg31226-tbl-0001){ref-type="table"} shows the distribution of characteristics in the patients with PDAC and the healthy controls. The mean age (mean ± *SD*) of cases and controls were 64.56 + 12.11 years and 63.31 + 9.40 years, respectively, and there was no significant difference (*p* = .060). Alcohol consumption and incidence of diabetes were also not significantly different between the two groups (*p* = .086 and *p* = .093, respectively). There was a significant difference in the distribution of sex, tobacco consumption, and family history of cancer between the two groups (*p* = .005, *p* \< .001, and *p* = .009, respectively). Specially, the frequencies of males, smokers, or individuals with family history of cancer were much higher in cases than controls (60.44% versus 48.33%; 30.77% versus 17.73%; 21.25% versus 12.64%, respectively).

###### 

Distribution of genetic characteristics in cases and controls

  Characteristics            Cases (*n* = 273)   Controls (*n* = 269)   *p*                                                     
  -------------------------- ------------------- ---------------------- ----------------------------------------------- ------- -------------------------------------------------
  Age (year) mean ± *SD*     64.56 ± 12.11       63.31 ± 9.40           .060[^a^](#mgg31226-note-0002){ref-type="fn"}           
  Gender                                                                                                                        
  Male                       165                 60.44                  130                                             48.33   .005[^b^](#mgg31226-note-0003){ref-type="fn"}
  Female                     108                 39.56                  139                                             51.67   
  Smoking                                                                                                                       
  Ever                       84                  30.77                  45                                              16.73   \<.001[^b^](#mgg31226-note-0003){ref-type="fn"}
  Never                      189                 69.23                  224                                             83.27   
  Drinking                                                                                                                      
  Ever                       49                  17.95                  34                                              12.64   .086[^b^](#mgg31226-note-0003){ref-type="fn"}
  Never                      224                 82.05                  235                                             87.36   
  Diabetes                                                                                                                      
  Yes                        51                  18.68                  36                                              13.38   .093[^b^](#mgg31226-note-0003){ref-type="fn"}
  No                         222                 81.32                  233                                             86.62   
  Family history of cancer                                                                                                      
  Yes                        58                  21.25                  34                                              12.64   .009[^b^](#mgg31226-note-0003){ref-type="fn"}
  No                         215                 78.75                  235                                             87.36   

Mann--Whitney U test.

McNemar test.
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3.2. Association between genetic polymorphisms and PDAC susceptibility {#mgg31226-sec-0013}
----------------------------------------------------------------------

All genotype and allele frequencies of the SNPs examined are presented in Table [2](#mgg31226-tbl-0002){ref-type="table"}. The distribution of these genotypes in each group did not deviate from the Hardy--Weinberg equilibrium (*p* \> .05). After adjustment for confounding factors (age, sex, smoking, drinking, diabetes, and family history of cancer) in an unconditional logistic regression model, patients with PDAC possessed significantly lower frequencies of genotypes AG, GG, and allele G at rs4148737 compared with the controls (26.79% versus 45.73%, *p* \< .001; 7.17% versus 21.79%, *p* \< .001; 20.57% versus 44.66%, *p* \< .001, respectively). Furthermore, subjects with genotypes AG, GG, and allele G were less susceptible to developing PDAC (OR = 0.29, 95% CI: 0.19--0.43; OR = 0.16, 95% CI: 0.09--0.30; OR = 0.32, 95% CI: 0.24--0.43, respectively). No significant differences were observed between the frequencies of any other SNPs between patients with PDAC and the control group (*p* \> .05).

###### 

Association between the related genotypes and alleles and PDAC risk

  Genotype     Cases (*n* = 273)   Controls (*n* = 269)   Crude OR (95% CI)   *p*     Adjusted OR[^a^](#mgg31226-note-0004){ref-type="fn"} (95% CI)   *p* [^a^](#mgg31226-note-0004){ref-type="fn"}                           
  ------------ ------------------- ---------------------- ------------------- ------- --------------------------------------------------------------- ----------------------------------------------- ----------------------- ------------
  rs1045642    267                 238                                                                                                                                                                                        
  CC           82                  30.71                  72                  30.25   1.00                                                            ---                                             1.00                    ---
  CT           118                 44.19                  127                 53.36   0.82 (0.54--1.22)                                               .323                                            0.76 (0.50--1.15)       .190
  TT           67                  25.09                  39                  16.39   1.51 (0.91--2.50)                                               .111                                            1.50 (0.89--2.51)       .126
  C Allele     282                 52.81                  271                 56.93   1.00                                                            ---                                             1.00                    ---
  T Allele     252                 47.19                  205                 43.07   1.18 (0.92--1.51)                                               .189                                            1.16 (0.90--1.49)       .256
  rs3789243    265                 244                                                                                                                                                                                        
  CC           115                 43.4                   111                 45.49   1.00                                                            ---                                             1.00                    ---
  CT           119                 44.91                  110                 45.08   1.04 (0.72--1.51)                                               .818                                            1.04 (0.72--1.52)       .829
  TT           31                  11.7                   23                  9.43    1.30 (0.71--2.37)                                               .389                                            1.37 (0.74--2.52)       .315
  C Allele     349                 59.45                  332                 60.14   1.00                                                            ---                                             1.00                    ---
  T Allele     238                 40.55                  220                 39.86   1.10 (0.85--1.43)                                               .46                                             1.13 (0.87--1.48)       .355
  rs4148737    265                 234                                                                                                                                                                                        
  AA           175                 66.04                  76                  32.48   1.00                                                            ---                                             1.00                    ---
  AG           71                  26.79                  107                 45.73   0.29 (0.19--0.43)                                               \<.001                                          **0.29 (0.19--0.43)**   **\<.001**
  GG           19                  7.17                   51                  21.79   0.16 (0.09--0.29)                                               \<.001                                          **0.16 (0.09--0.30)**   **\<.001**
  A Allele     421                 79.43                  259                 55.34   1.00                                                            ---                                             1.00                    ---
  G Allele     109                 20.57                  209                 44.66   0.32 (0.24--0.42)                                               \<.001                                          **0.32 (0.24--0.43)**   **\<.001**
  rs693        262                 228                                                                                                                                                                                        
  CC           234                 89.31                  199                 87.28   1.00                                                            ---                                             1.00                    ---
  TC           26                  9.92                   19                  8.33    1.16 (0.63--2.17)                                               .632                                            1.15 (0.61--2.17)       .671
  TT           2                   0.76                   10                  4.39    0.17 (0.04--0.79)                                               .023                                            0.18 (0.04--0.85)       .030
  C Allele     494                 94.27                  417                 91.45   1.00                                                            ---                                             1.00                    ---
  T Allele     30                  5.73                   39                  8.55    0.65 (0.40--1.06)                                               .086                                            0.64 (0.39--1.06)       .083
  rs1042031    267                 243                                                                                                                                                                                        
  GG           231                 86.52                  211                 86.83   1.00                                                            ---                                             1.00                    ---
  AG           36                  13.48                  30                  12.35   1.10 (0.65--1.84)                                               .729                                            1.04 (0.61--1.76)       .897
  AA           0                   0                      2                   0.82    ---                                                             ---                                             ---                     ---
  G Allele     498                 93.26                  452                 93      1.00                                                            ---                                             1.00                    ---
  A Allele     36                  6.74                   34                  7       0.96 (0.59--1.56)                                               .873                                            0.92 (0.56--1.50)       .728
  rs12672038   267                 242                                                                                                                                                                                        
  GG           146                 54.68                  134                 55.37   1.00                                                            ---                                             1.00                    ---
  AG           106                 39.7                   92                  38.02   1.06 (0.73--1.52)                                               .764                                            1.05 (0.72--1.52)       .811
  AA           15                  5.62                   16                  6.61    0.86 (0.41--1.81)                                               .692                                            0.90 (0.43--1.92)       .793
  G Allele     398                 74.53                  360                 74.38   1.00                                                            ---                                             1.00                    ---
  A Allele     136                 25.47                  124                 25.62   0.99 (0.75--1.32)                                               .956                                            0.99 (0.75--1.32)       .969
  rs1997623    267                 245                                                                                                                                                                                        
  CC           248                 92.88                  219                 89.39   1.00                                                            ---                                             1.00                    ---
  AC           17                  6.37                   24                  9.8     0.63 (0.33--1.20)                                               .155                                            0.66 (0.34--1.27)       .209
  AA           2                   0.75                   2                   0.82    0.88 (0.12--6.32)                                               .901                                            1.11 (0.15--8.07)       .919
  C Allele     513                 96.07                  462                 94.29   1.00                                                            ---                                             1.00                    ---
  A Allele     21                  3.93                   28                  5.71    0.68 (0.38--1.21)                                               .185                                            0.72 (0.40--1.29)       .969
  rs3807987    260                 232                                                                                                                                                                                        
  GG           158                 60.77                  142                 61.21   1.00                                                            ---                                             1.00                    ---
  AG           85                  32.69                  80                  34.48   0.95 (0.65--1.40)                                               .812                                            0.93 (0.63--1.37)       .701
  AA           17                  6.54                   10                  4.31    1.53 (0.68--3.45)                                               .307                                            1.61 (0.71--3.67)       .256
  G Allele     401                 81.84                  364                 78.45   1.00                                                            ---                                             1.00                    ---
  A Allele     89                  18.16                  100                 21.55   1.08 (0.80--1.46)                                               .616                                            1.07 (0.79--1.45)       .669
  rs7804372    267                 241                                                                                                                                                                                        
  TT           158                 59.18                  144                 59.75   1.00                                                            ---                                             1.00                    ---
  AT           109                 40.82                  97                  40.25   1.02 (0.72--1.46)                                               .895                                            1.00 (0.70--1.44)       .997
  AA           0                   0                      0                   0       ---                                                             ---                                             ---                     ---
  T Allele     425                 79.59                  385                 79.88   1.00                                                            ---                                             1.00                    ---
  A Allele     109                 20.41                  97                  20.12   1.02 (0.75--1.38)                                               .909                                            1.00 (0.73--1.37)       .997
  rs9034       266                 243                                                                                                                                                                                        
  CC           226                 84.96                  211                 86.83   1.00                                                            ---                                             1.00                    ---
  TC           40                  15.04                  26                  10.7    1.44 (0.85--2.44)                                               .179                                            1.38 (0.81--2.36)       .242
  TT           0                   0                      26                  2.47    ---                                                             ---                                             ---                     ---
  C Allele     492                 92.48                  448                 85.17   1.00                                                            ---                                             1.00                    ---
  T Allele     40                  7.52                   78                  14.83   0.96 (0.60--1.52)                                               .857                                            0.96 (0.60--1.53)       .853
  rs2505568    264                 231                                                                                                                                                                                        
  TT           41                  15.53                  42                  18.18   1.00                                                            ---                                             1.00                    ---
  AT           223                 84.47                  189                 81.82   1.21 (0.75--1.94)                                               .431                                            1.14 (0.71--1.85)       .580
  AA           0                   0                      0                   0       ---                                                             ---                                             ---                     ---
  T Allele     305                 57.77                  273                 59.09   1.00                                                            ---                                             1.00                    ---
  A Allele     223                 42.23                  189                 40.91   1.06 (0.82--1.36)                                               .673                                            1.04 (0.80--1.34)       .783
  rs61330082   269                 260                                                                                                                                                                                        
  CC           98                  36.43                  81                  31.15   1.00                                                            ---                                             1.00                    ---
  CT           91                  33.83                  94                  36.15   0.80 (0.53--1.21)                                               .289                                            0.76 (0.50--1.16)       .201
  TT           80                  29.74                  85                  32.69   0.78 (0.51--1.19)                                               .246                                            0.73 (0.47--1.12)       .150
  C Allele     287                 53.35                  256                 49.23   1.00                                                            ---                                             1.00                    ---
  T Allele     251                 46.65                  264                 50.77   0.85 (0.67--1.08)                                               .181                                            0.83 (0.65--1.06)       .135

Bold values in this table indicates the significant differences (*P* \< .05).

Unconditional logistic regression adjusted for risk factors (age, gender, tobacco smoking, alcohol consumption, diabetes, and family history of cancer).
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3.3. Stratification analyses of ABCB1 genetic polymorphisms and PDAC susceptibility {#mgg31226-sec-0014}
-----------------------------------------------------------------------------------

To evaluate the effect of genetic polymorphism at rs4148737 on the susceptibility of PDAC, subjects were stratified based on age, sex, smoking status, drinking status, presence of diabetes, and family history of cancer (Table [3](#mgg31226-tbl-0003){ref-type="table"}). Compared with genotype AA, significantly decreased frequencies of genotypes AG and GG were detected among male patients with PDAC (adjusted OR = 0.22, 95% CI: 0.13--0.37), female cases (adjusted OR = 0.27, 95% CI: 0.15--0.47), patients in different age brackets (\<60‐year‐old, adjusted OR = 0.18, 95% CI: 0.09--0.36; 60‐ to 80‐year‐old, adjusted OR = 0.30, 95% CI: 0.19--0.49; \>80‐year‐old, adjusted OR = 0.09, 95% CI: 0.01--0.69, respectively), patients who had previously smoked or did smoke (adjusted OR = 0.22, 95% CI: 0.10--0.51), patients who never smoked (adjusted OR = 0.25, 95% CI: 0.16--0.39), patients who consumed alcohol (adjusted OR = 0.21, 95% CI: 0.08--0.56), patients who did consume alcohol (adjusted OR = 0.25, 95% CI: 0.17--0.38), patients with diabetes (adjusted OR = 0.36, 95% CI: 0.13--0.99), patients without diabetes (adjusted OR = 0.24, 95% CI: 0.16--0.36), patients with a family history of cancer (adjusted OR = 0.11, 95% CI: 0.04--0.33), and without a family history (adjusted OR = 0.28, 95% CI: 0.19--0.42).

###### 

Stratification analyses of rs4148737 genotypes and PDAC risk

  Variable                   rs4148737 (case/control)   *p* [^a^](#mgg31226-note-0005){ref-type="fn"}   Adjusted OR[^a^](#mgg31226-note-0005){ref-type="fn"} (95% CI)   
  -------------------------- -------------------------- ----------------------------------------------- --------------------------------------------------------------- ---------
  Gender                                                                                                                                                                
  Male                       108/37                     53/80                                           1.00                                                            \<0.001
  0.22 (0.13--0.37)                                                                                                                                                     
  Female                     67/39                      37/78                                           1.00                                                            \<0.001
  0.27 (0.15--0.47)                                                                                                                                                     
  Age                                                                                                                                                                   
  \<60                       62/25                      26/54                                           1.00                                                            \<0.001
  0.18 (0.09--0.36)                                                                                                                                                     
  60--80                     96/49                      59/98                                           1.00                                                            \<0.001
  0.30 (0.19--0.49)                                                                                                                                                     
  \>80                       17/2                       5/6                                             1.00                                                            0.021
  0.09 (0.01--0.69)                                                                                                                                                     
  Smoking                                                                                                                                                               
  Ever                       56/15                      25/27                                           1.00                                                            \<0.001
  0.22 (0.10--0.51)                                                                                                                                                     
  Never                      119/61                     65/131                                          1.00                                                            \<0.001
  0.25 (0.16--0.39)                                                                                                                                                     
  Drinking                                                                                                                                                              
  Ever                       36/13                      12/19                                           1.00                                                            0.002
  0.21 (0.08--0.56)                                                                                                                                                     
  Never                      139/63                     78/139                                          1.00                                                            \<0.001
  0.25 (0.17--0.38)                                                                                                                                                     
  Diabetes                                                                                                                                                              
  Yes                        31/11                      18/20                                           1.00                                                            0.049
  0.36 (0.13--0.99)                                                                                                                                                     
  No                         144/65                     72/138                                          1.00                                                            \<0.001
  0.24 (0.16--0.36)                                                                                                                                                     
  Family history of cancer                                                                                                                                              
  Yes                        38/9                       17/25                                           1.00                                                            \<0.001
  0.11 (0.04--0.33)                                                                                                                                                     
  No                         127/67                     73/133                                          1.00                                                            \<0.001
  0.28 (0.19--0.42)                                                                                                                                                     

Adjusted for gender, age, tobacco smoking, alcohol consumption, diabetes, and family history of cancer (besides stratified factors accordingly) in unconditional logistic regression.
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3.4. Association between ABCB1 haplotypes and PDAC susceptibility {#mgg31226-sec-0015}
-----------------------------------------------------------------

After identifying the genotypes of the three SNPs of ABCB1, eight haplotypes were constructed using PHASE version 2.1 software. Table [4](#mgg31226-tbl-0004){ref-type="table"} shows the distribution of the estimated haplotypes in each group. It implied that haplotypes ACC (rs4148737A‐rs1045642C‐rs3789243C) and ATC (rs4148737A‐rs1045642T‐rs3789243C) were present more frequently in patients with PDAC compared with the control group (18.11% versus 12.87%; 33.94% versus 22.09%, respectively), whereas haplotypes GCC (rs4148737G‐rs1045642C‐rs3789243C) and GTC (rs4148737G‐rs1045642T‐rs3789243C) were present less frequently in the patients with PDAC compared with the control group (11.93% versus 19.27%; 0.64% versus 12.68%, respectively). Using unconditional logistic regression models adjusted for the confounding factors, the association between haplotypes and PDAC risk was calculated and is shown in Table [5](#mgg31226-tbl-0005){ref-type="table"}. Carriers with haplotype ACC (a/‐ + a/a) or ATC (c/‐ + c/c) were observed to have increased susceptibility to PDAC (OR = 1.58, 95% CI: 1.02--2.45; OR = 2.16, 95% CI: 1.47--3.18, respectively), but patients with haplotype GCC (e/‐ + e/e) or GTC (g/‐ + g/g) had reduced susceptibility (OR = 0.46, 95% CI: 0.30--0.71; OR = 0.04, 95% CI: 0.01--0.14, respectively). None of the other haplotypes presented any significant differences (*p* \> .05).

###### 

Distribution of the estimated haplotype frequencies

  Haplotypes   SNP positions   Cases (*n* = 228)   Controls (*n* = 217)                      
  ------------ --------------- ------------------- ---------------------- ----- ------- ---- -------
  1            A               C                   C                      82    18.11   56   12.87
  2            A               C                   T                      77    16.9    60   13.92
  3            A               T                   C                      155   33.94   96   22.09
  4            A               T                   T                      44    9.55    32   7.35
  5            G               C                   C                      54    11.93   84   19.27
  6            G               C                   T                      34    7.44    45   10.39
  7            G               T                   C                      3     0.64    55   12.68
  8            G               T                   T                      7     1.49    6    1.43

Calculated by PHASE 2.1 software.
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###### 

Association between the related haplotypes and PDAC risk

  Haplotype                                      Cases (*n* = 228)   Controls (*n* = 217)   Crude OR (95% CI)   *p*     Adjusted OR[^a^](#mgg31226-note-0007){ref-type="fn"} (95% CI)   *p* [^a^](#mgg31226-note-0007){ref-type="fn"}                           
  ---------------------------------------------- ------------------- ---------------------- ------------------- ------- --------------------------------------------------------------- ----------------------------------------------- ----------------------- ------------
  a = ACC                                                                                                                                                                                                                                                       
  −/−[^b^](#mgg31226-note-0008){ref-type="fn"}   159                 69.74                  172                 80.18   1.00                                                            ---                                             1.00                    ---
  a/− + a/a                                      69                  30.26                  45                  19.82   1.66 (1.08--2.56)                                               .022                                            **1.58 (1.02--2.45)**   **.041**
  b = ACT                                                                                                                                                                                                                                                       
  −/−                                            164                 71.93                  167                 79.96   1.00                                                            ---                                             1.00                    ---
  b/− + b/b                                      64                  28.07                  50                  23.04   1.30 (0.85--2.00)                                               .225                                            1.28 (0.83--1.97)       .271
  c = ATC                                                                                                                                                                                                                                                       
  −/−                                            97                  37.28                  136                 62.67   1.00                                                            ---                                             1.00                    ---
  c/− + c/c                                      131                 62.72                  81                  37.33   2.27 (1.56--3.32)                                               0                                               **2.16 (1.47--3.18)**   **\<.001**
  d = ATT                                                                                                                                                                                                                                                       
  −/−                                            189                 82.89                  191                 88.02   1.00                                                            ---                                             1.00                    ---
  d/− + d/d                                      39                  17.11                  26                  11.98   1.52 (0.89--2.59)                                               .128                                            1.42 (0.82--2.44)       .212
  e = GCC                                                                                                                                                                                                                                                       
  −/−                                            184                 80.7                   140                 64.52   1.00                                                            ---                                             1.00                    ---
  e/− + e/e                                      44                  19.3                   77                  35.48   0.43 (0.28--0.67)                                               0                                               **0.46 (0.30--0.71)**   **\<.001**
  f = GCT                                                                                                                                                                                                                                                       
  −/−                                            199                 87.28                  178                 82.03   1.00                                                            ---                                             1.00                    ---
  f/− + f/f                                      29                  12.72                  39                  17.97   0.67 (0.39--1.12)                                               .125                                            0.66 (0.39--1.11)       .119
  g = GTC                                                                                                                                                                                                                                                       
  −/−                                            225                 98.68                  168                 77.42   1.00                                                            ---                                             1.00                    ---
  g/− + g/g                                      3                   1.32                   49                  22.58   0.05 (0.01--0.15)                                               0                                               **0.04 (0.01--0.14)**   **\<.001**
  h = GTT                                                                                                                                                                                                                                                       
  −/−                                            221                 96.93                  211                 97.24   1.00                                                            ---                                             1.00                    ---
  h/− + h/h                                      7                   3.07                   6                   2.76    1.11 (0.37--3.37)                                               .849                                            1.01 (0.33--3.11)       .99

Bold values in this table indicates the significant differences (*P* \< .05).

Unconditional logistic regression adjusted for risk factors (age, gender, tobacco smoking, alcohol consumption, diabetes, and family history of cancer).

Indicates any haplotype, for example: a/− denotes the haplotype a = ACC combined with any other haplotypes.
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4. DISCUSSION {#mgg31226-sec-0016}
=============

Between 2014 and 2018, the 5‐year survival rate of pancreatic cancer increased from 6% to 9% (Bray et al., [2018](#mgg31226-bib-0004){ref-type="ref"}), suggesting that although progress is being made, there is still a need to improve the treatments and outcomes. Pancreatic cancer remains one of the most lethal malignancies, with poor prognoses and a mortality/incidence ratio of 94% (Bray et al., [2018](#mgg31226-bib-0004){ref-type="ref"}). Due to its atypical clinical features, nonspecific, diagnostic tools which lack specificity and no definitive cures for patients with advanced‐stage pancreatic cancer, the 1‐year survival rate of pancreatic cancer has been significantly reduced from 25% to \<5% (Sarnecka, Zagozda, & Durlik, [2016](#mgg31226-bib-0035){ref-type="ref"}). Despite advances in our understanding of this disease and potential risk factors, and advances in diagnostic tools to improve early detection, the incidence is estimated to increase with a predicted 355,317 new cases globally in 2040 (Rawla et al., [2019](#mgg31226-bib-0030){ref-type="ref"}). Thus, it is necessary to improve our understanding of the pathogenesis of PDAC to improve the preventative, diagnostic, and therapeutic approaches. In particular, discovering new tumor biomarkers is of great significance as these biomarkers are valuable tools for improving the accuracy of diagnosis, prevention, and therapy. Among the pathogenic factors underlying the development of cancer, SNPs have been demonstrated to be associated with altered function of methylation enzymes, folate metabolism, inflammation, cell cycle, DNA repair, and also oncogenes, which are suspected to serve a role in the carcinogenesis of PDAC.

ABCB1 is an efflux protein pump, which transports toxic endogenous substances, drugs, and xenobiotics out of normal tissues and cancer cells (Hartmann, Kim, & Piquette‐Miller, [2001](#mgg31226-bib-0018){ref-type="ref"}). The intronic SNPs at rs4148737 map to a weakly transcribed region, but also overlaps with a weak enhancer in GM12878 and in a RUNX3 ChIP‐seq cluster in the same lymphoblastoid cell line. It was predicted to overlap with a DNase hypersensitive region in the lymphoblastoid cell line and other cell lines and alter EBF, ERα‐a, and Hic1 regulatory motifs (Ruiz‐Pinto et al., [2016](#mgg31226-bib-0032){ref-type="ref"}). Cells with the wild‐type SNPs of *ABCB1* showed drug resistance in a pancreatic cancer cell line (Kasuya et al., [2012](#mgg31226-bib-0023){ref-type="ref"}), and polymorphic variants of *ABCB1* were observed to predict improved therapeutic efficacy and survival for patients with potentially resectable pancreatic cancer (Tanaka, Okazaki, Suzuki, Abbruzzese, & Li, [2011](#mgg31226-bib-0042){ref-type="ref"}). However, there are no studies on the effect of its genetic polymorphism on susceptibility to PDAC, to the best of our knowledge. In the present study, the frequencies of genotypes AG and GG, as well as allele G in *ABCB1* rs4148737 were significantly lower in patients with PDAC compared with the controls. Therefore, these variant genotypes and alleles may decrease an individual susceptibility to PDAC. This interpretation of the result agrees with ABCB1's possible protective functions and is similar to previous studies on outcomes of treatments in patients with Ewing sarcoma (Ruiz‐Pinto et al., [2016](#mgg31226-bib-0032){ref-type="ref"}) and osteosarcoma survival following chemotherapy (He et al., [2013](#mgg31226-bib-0019){ref-type="ref"}). Stratification by sex, age, smoking status, drinking status, diabetes, and family history of cancer showed that individuals with genotypes AG and GG still exhibited a reduced risk of developing PDAC, highlighting the protective role of these SNPs.

Additionally, although *NAMPT* rs2505568 and rs9034 are located in the 3' untranslated region, which may affect NAMPT expression, their polymorphisms were found to be independent of the development of dilated cardiomyopathy, esophageal squamous cell carcinoma (ESCC), and bladder cancer (Dou et al., [2015](#mgg31226-bib-0051){ref-type="ref"}; Zhang et al., [2015](#mgg31226-bib-0050){ref-type="ref"}; Zhang, Zhou, et al., [2014](#mgg31226-bib-0051){ref-type="ref"}). *APOB* rs1997623 and rs12672038 were reported to have no influence on ESCC or gastric cancer (Rawla et al., [2019](#mgg31226-bib-0030){ref-type="ref"}; Zhang, Hu, et al., [2014](#mgg31226-bib-0052){ref-type="ref"}). As these four SNPs are not associated with PDAC, these results are consistent with previous studies.

The other SNPs tested in the present study were determined to not be significantly associated with the development of PDAC, which differs from previous studies in different types of cancer. A silent mutation at *ABCB1* rs1045642 may decrease the expression levels of the mRNA and protein products, or alter the protein structure and substrate affinity (Cascorbi, [2006](#mgg31226-bib-0007){ref-type="ref"}; Kimchi‐Sarfaty et al., [2007](#mgg31226-bib-0025){ref-type="ref"}). Genotype TT was found to significantly increase the overall risk of gastric cancer in Iranian individuals and upper aerodigestive tract cancer in Indian individuals (Sabahi et al., [2010](#mgg31226-bib-0033){ref-type="ref"}; Sam et al., [2007](#mgg31226-bib-0034){ref-type="ref"}), and was associated with colorectal cancer and multiple myeloma in French individuals (Falkowski et al., [2017](#mgg31226-bib-0012){ref-type="ref"}; Razi, Anani Sarab, Omidkhoda, & Alizadeh, [2018](#mgg31226-bib-0031){ref-type="ref"}). There is a correlation between SNPs at rs3789243 with colorectal cancer (Andersen et al., [2013](#mgg31226-bib-0002){ref-type="ref"}). Furthermore, SNPs at *APOB* rs693 resulting in amino acid substitution and SNPs at rs104203, which result in a silent mutation, have been reported to be associated with dyslipidemia (Tsunoda, Harihara, Tanabe, & Dashnyam, [2012](#mgg31226-bib-0043){ref-type="ref"}) and an increased risk of breast cancer in Chinese individuals (Liu et al., [2013](#mgg31226-bib-0026){ref-type="ref"}). *CAV1* rs3807987 and rs7804372 are located in introns, but intron polymorphisms may influence CAV1 expression levels and protein function by compounding with nearby polymorphisms, alternative splicing, and affecting the stability of mRNA during the progression of the cancer. These two SNPs are associated with susceptibility to ESCC, breast, and gastric cancer (Wang et al., [2014](#mgg31226-bib-0045){ref-type="ref"}; Yan et al., [2019](#mgg31226-bib-0046){ref-type="ref"}; Zhang, Hu, et al., [2014](#mgg31226-bib-0052){ref-type="ref"}). *NAMPT* rs61330082 in the promoter region may influence NAMPT structure, function, or expression, which is similar to its role in increasing the risk of ESCC and bladder cancer (Zhang et al., [2015](#mgg31226-bib-0050){ref-type="ref"}; Zhang, Zhou, et al., [2014](#mgg31226-bib-0051){ref-type="ref"}).

The varying results of the seven SNPs and their effects on tumorigenesis between the present and previous studies may primarily be due to different tumor locations, tumor pathological status, tumor differentiation status, demographics, and limited number of samples available.

To analyze the combined effects of multiple loci, haplotype analyses were used to assess genetic susceptibility with increased accuracy. Based on the genotypes at *ABCB1* rs4148737A, rs1045642, and rs3789243, the presence of haplotypes ACC and ATC was constructed and positively correlated with the development of PDAC, whereas haplotypes GCC and GTC protected carriers from PDAC. Thus, the impact of allele G or A at rs4148737 among the three SNPs was thus determined to be important, which is consistent with the positive effect of allele A on PDAC tumorigenesis.

Due to a lower incidence, atypical clinical manifestations, insensitive early diagnostic tools, rapid development of the cancer, and limited treatment regimens for patients with advanced‐staged cancer, the number of PDAC cases is significantly lower compared with other types of cancer of the digestive system, particularly cases with identified pathological results. The strengths of the present study include the relatively large sample size from the same geographical area. However, the present study has some limitations. Sample size determination was not based on power calculations, which may affect the accuracy of the results to a certain extent, particularly as the sample sizes were smaller when the patients were stratified. These results need to be further confirmed using a larger sample from patients in regions with a higher incidence of PDAC, and from different ethnicities. Additionally, if the study participants were relatively homogeneous in terms of general characteristics, genetic backgrounds, and environmental risk factors, the results would be more accurate. Gene--environment interaction studies and functional studies are required to confirm these results and determine the effects of *ABCB1* genetic polymorphisms on PDAC.

In summary, the present study showed that genetic polymorphism of *ABCB1* rs4148737 was significantly associated with PDAC susceptibility in Chinese patients. Genotypes AG and GG, allele G, as well as haplotypes GCC and GTC may be protective predictive factors for PDAC. Therefore, SNPs at rs4148737 may serve as an efficient genetic susceptibility marker, and possibly a potential target for development of tools for early diagnosis, genetic prediction, and individualized genetic therapy in the future.
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